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Purpose: This study assessed the feasibility and mid-term outcomes in the treatment of type II endoleak using
transcatheter transcaval embolization (TTE).
Methods: During an 8-month period, 12 patients underwent TTE. After direct transcaval puncture of the aneurysm sac,
embolization was performed by injecting thrombin and placing coils. Systemic and intrasac pressures were recorded
throughout the entire procedure. Computed tomography (CT) scans were performed at 24 hours, 30 days, 6months, and
1 year after TTE to evaluate endoleaks and changes in sac diameter. Technical success was defined as the feasibility of the
procedure; clinical success was defined as no evidence of leaks during the follow-up evaluation.
Results: TTE was feasible in 11 of 12 patients (technical success 92%). The mean systemic pressure was 117 mmHg. The
mean intrasac pressure before embolization was 75 mmHg (range, 39 to 125 mmHg), 16.5 mmHg (range, 7 to 40 mm
Hg) in 10 patients after embolization, and it increased in one patient. CT scans at 24 hours showed stable contrast
medium inside the sac in 10 patients. Onlyminor complications were observed during follow-up. At the 1-year follow-up,
no recurrence of leaks was noted, and sac diameter was reduced in 10 of 11 patients. As a result, TTE clinical success was
obtained in 10 (83%) of 12 patients.
Conclusion: TTE appears to be a feasible technique for the complete exclusion of type II endoleaks. Technical and clinical
successes are comparable with other treatment strategies, and TTE should be considered an alternative to direct
translumbar puncture of the aneurysm sac. ( J Vasc Surg 2007;45:1120-7.)The endovascular repair of abdominal aortic aneurysms
(EVAR) may be complicated by the incomplete exclusion
of blood flow to the aneurysm sac. This complication has
been defined as endoleak by White et al.1 The incomplete
sealing off of the graft to the native vascular system is
defined as type I endoleak. Leaks related to fabric tears,
graft disconnection, or disintegration are designated as type
III.2-4 Type I and III endoleaks lead to direct arterial flow
into the aneurysm sac and are considered technical and
clinical failures of EVAR treatment. Endovascular or surgi-
cal treatment is mandatory in these conditions.3,4
Notably, when an EVAR is successful, as defined as
complete sealing at the attachment sites, blood flow into
the aneurysm sac can still occur. The reperfusion is usually
due to the patency of the collateral branches, such as from
the inferior mesenteric artery (IMA) or the lumbar arteries,
or both. This condition is known as a type II endoleak.2-4
The management of patients with type II endoleak is a
source of continuing debate in the literature. Even though
type II endoleak can lead to the late rupture of the aneu-
rysm sac and resultant clinical failure of endovascular treat-
ment, there is currently no consensus on the best treatment
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1120strategy.5 Transcatheter transcaval embolization (TTE)
was reported as a technique for the treatment of type Il
endoleaks, suggesting superior management of all steps in
the embolization procedure compared with the direct
translumbar approach.6 In this prospective study, we eval-
uated the feasibility and mid-term results in 12 consecutive
patients who underwent this approach.
MATERIAL AND METHODS
Patient group and study design. The Institutional
Review Board approved our study, and all patients provided
informed consent for the procedure. TTE was proposed
instead of the direct translumbar approach as the initial
treatment of type II endoleak and in cases where transarte-
rial embolization failed. The indications for treatment were
the same: evidence of type II endoleak at the 12-month
follow-up or a significant increase in aneurysm sac diameter
(5 mm compared with the diameter highlighted at a
previous examination) after at least 6 months of follow-up.
From September 2004 to April 2005, 12 patients under-
went TTE. They previously had undergone EVAR for
infrarenal abdominal aortic aneurysms, and a follow-up
computed tomography (CT) scan showed type II endoleak,
or at least endotension.
The study population consisted of 11 men and 1
woman. The mean age  standard deviation was 79  5.3
years (range, 68 to 85 years). Patient clinical characteristics
are presented in Table I. Two patients had been treated
with Excluder stent grafts (W. L. Gore & Associates, Flag-
staff, Ariz), three with AneuRx grafts (Medtronic, Minne-
apolis, Minn), and seven with Talent grafts (Medtronic).
The mean time between EVAR and TTE was 47 months
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diameter before EVAR was 63 mm (range, 50 to 78 mm),
whereas on repeat CT scan before TTE it was 71 13 mm
(range, 50 to 88 mm) with a mean increase in diameter of 8
mm (range, 0 to 30 mm).
Type II endoleak was clearly demonstrated on CT scan
in 9 patients, eight of whom had a significant increase in
diameter, and one patient was found to have a large en-
doleak without a significant increase in diameter for more
than 12 months. In three patients, an increase in maximum
aneurysm diameter (5 mm compared with the diameter
highlighted at a previous examination) was demonstrated
on CT angiography, without evidence of blood flow inside
the aneurysm sac. In these three patients, we hypothesized
that a very slow flow reperfusion was present that imaging
techniques could not visualize.
Before TTE, a selective digital subtraction angiography
(DSA) was performed in nine of 12 patients to highlight the
presence and source of endoleak. A type II endoleak was
demonstrated in four patients: in two patients it was from
the inferior mesenteric artery (IMA); whereas in the other
two it came from the lumbar arteries. They underwent
endovascular treatment consisting of embolizing the origin
of the IMA or closing the afferent lumbar branches to the
aneurysm sac. Immediate technical success was achieved in
only two patients. One had a type II endoleak from the
IMA, and the other had a type II endoleak coming from the
lumbar arteries. In both of these patients, a recurrence of
their leaks was seen on CT scan 30 days after the emboli-
zation.
In the first 24 hours after TTE, all patients were ob-
served in the surgical department during which central
venous blood pressure, arterial pressure, heart rate, and
peripheral oxygen saturation were monitored. They under-
went unenhanced CT scan at 24 hours. They were all
discharged at 48 hours and were followed up with a clinical
examination and CT scan at approximately 1 month, 6
months, and at 1 year. We evaluated the technical and
clinical success of these patients. The technical success was
defined as the feasibility of transcaval puncture of the
aneurysm sac, and the clinical success was defined as the
Table I. Patient characteristics before transcatheter
transcaval embolization
Characteristics Patients (n)
Hypertension 9
Hyperlipidemia 2
Diabetes 2
Chronic renal failure 5
Prior MI/angina 2
Previous cancer surgery 6
Anticoagulant therapy 6
ASA class 1 —
ASA class 2 4
ASA class 3 5
ASA class 4 3
MI, Myocardial infarction; ASA, American Society of Anesthesiologists.absence of type II endoleak on follow-up examination.Preoperative imaging. Preoperative CT scan was per-
formed on all patients on a Somatom Plus 4 CT scanner
(Siemens, Erlangen, Germany). According to a standard
triphasic protocol, helical images were obtained from the
celiac artery to the common femoral arteries, both before
and after intravenous administration of 120mL of nonionic
contrast medium with a flow rate of 3 mL/s. Before the
injection of contrast medium, acquisition parameters for
spiral CT were 8-mm collimation, 5-mm reconstruction,
and 1.5 pitch. After contrast medium injection, acquisition
parameters for spiral CT were 5-mm collimation, 3 mm
reconstruction, and 1.5 pitch. Images were obtained in
both the arterial and venous phases. The scanning delay for
the arterial phase was usually set at 30 seconds and the
venous/delayed phase was set at 120 seconds so that late
endoleaks could be identified. An experienced radiologist
reviewed the images and evaluated themaximum transverse
aneurysm diameter and the presence and origin of en-
doleaks, which were defined as the evidence of contrast
enhancement within the aneurysm sac in the postcontrast
medium phases.
Preoperative DSA was performed in 9 of 12 patients on
a Multistar angiography scanner (Siemens, Erlangen, Ger-
many). After patients were given a local anesthetic (2%
lidocaine) and transfemoral arterial percutaneous access
was obtained, a 5F pigtail catheter was advanced into the
abdominal aorta. Aortography in the anteroposterior pro-
jection was performed above the proximal end of the stent
graft with a 20-mL bolus injection of contrast at 10 mL/s.
A selective angiography of the superior mesenteric artery
was then performed by using a properly shaped catheter
with a 30-mL bolus injection at 5mL/s. If no endoleak was
demonstrated by selective catheterization, a Simmons 1
catheter (Terumo Europe NV, Leuven, Belgium) was then
pulled down into the stent graft just above the flow divider
and placed into the contralateral common iliac artery to
perform pelvic angiographies in the left and right anterior
oblique projections with a 16-mL bolus injection at 4
mL/s.
We concluded the diagnostic DSA by performing se-
lective angiography of the ipsilateral internal iliac artery by
using the Simmons 1 catheter and the same bolus injection
used for the contralateral common iliac artery. Whenever a
type II endoleak was identified, a superselective coil embo-
lization of the afferent vessels was attempted.
Transcatheter transcaval embolization. The proce-
dure was performed in the angiography suite (Multistar)
with the patient in a supine position. A percutaneous trans-
femoral vein approach was chosen in the first seven patients,
whereas in the next five patients we preferred percutaneous
access via the right jugular vein. We followed a standard
technique in almost all of the patients.
A 10F sheath is used to advance the introducer catheter
assembly with the curved guiding cannula (William Cook
Europe, Bjaeverskov, Denmark) into the inferior caval vein
over a guidewire (Fig 1, A). The wire is removed and the
system oriented to the stent graft. The system direction is
verified in the two fluoroscopic orthogonal projections (Fig
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cantly help the proper orienting of the aneurysm and the
introducer assembly. The shunt set must be completely
wedged along the caval wall at a site in which there is a tight
adhesion between the caval and aneurysm walls. When
there are no calcified walls, ultrasonographic guidance can
be helpful.
After checking for the system’s wedging against the
caval wall with a contrast injection, we introduce the flexi-
ble puncture needle and 5F catheter assembly into the
curved guiding cannula. The puncture was performed un-
der fluoroscopic control in all cases (Fig 1, D) and with
additional sonographic guidance in one case. After remov-
ing the flexible puncture needle, the success of the puncture
is demonstrated by blood dripping from the 5F catheter or
the intrasac pressure monitor, or both.
Once inside the sac, a 0.035-inch J hydrophilic guide-
wire (Terumo Corp, Tokyo, Japan) is advanced and en-
rolled into the sac (Fig 2, A). The placement of the needle/
Fig 1. Transcaval direct puncture of the aneurysm sac. A, A right
transjugular percutaneous access is used to place a 10F sheath and
a curved guiding cannula into the inferior vena cava. B, Antero-
posterior projection of cavography and (C) lateral projections
highlight the system’s wedging to caval walls at the selected
puncture site. D, The aneurysm sac is punctured with the flexible
needle.sheath system within the endoleak nidus is not alwayspossible, but the thrombus can be broken into small clots
by the guidewire as it enrolls inside the sac. To allow for the
advancement of the 5F catheter over the wire into the
aneurysm sac, a diagnostic angiography is performed with
the catheter just inside the aneurysm. We call this saccogra-
phy, and it is done to highlight the endoleak and to help
visualize the feeding vessels (Fig 2, B).
Embolization is done regardless of where the type II
endoleak nidus is by using thrombin (Tissucol Duo Im-
muno, Baxter, Rome, Italy) because it can spread inside the
aneurysm sac and fill it. Metallic MReye Embolization
Coils (William Cook, Bjaeverskov, Denmark) were used
with thrombin in patients with large endoleaks, with the
catheter tip placed directly inside the nidus. The emboliza-
tion is performed under fluoroscopic guidance and with
monitoring of the intrasac pressure (Fig 2, C).
Thrombin is injected at 1-mL boluses. After first bolus
Fig 2. Transcaval transcatheter embolization of the aneurysm sac
(same patient as in Fig 1). A, A hydrophilic wire is enrolled inside
the sac (arrowheads). B, A diagnostic angiography is performed,
contrast medium fills the aneurysm sac, and the endoleak is high-
lighted. C, Embolization is realized under fluoroscopic guidance
by placing coils and filling the sac with thrombin (arrows). D,
Cavography through the introducer sheath doe not demonstrate
lesions at the site of puncture. Coils and stable contrast medium are
highlighted inside the sac (arrows).injection, we wait 3 minutes. Another bolus of thrombin is
romb
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5F catheter or if a systolic-diastolic pressure still exists in the
aneurysm sac. We wait an additional 3 minutes and remea-
sure the intrasac pressure, after washing the 5F catheter
with few milliliters of saline solution.
Intrasac embolization is stopped only when there is no
more evidence of flow inside the aneurysm sac. This was
defined as no evidence of blood dripping from the 5F
catheter and that contrast is stable inside the sac. Stable
intrasac pressure within an aneurysm that had a previous
systolic-diastolic waveform or its reduction by a minimum
of 50 mm Hg, or both, was considered as further evidence
of successful embolization. At the end of all procedures, we
check for any lesions at the site of caval puncture by
performing a cavography through the sheath before remov-
ing the venous sheath (Fig 2, D).
Intrasac pressure measurement. Intrasac pressure
measurements are performed by using a pressure trans-
ducer for invasive pressure monitoring (Edwards Life-
sciences, Irvine, Calif) connected to a multiparametric
monitor Datex Engtrom S/5 (Datex Ohmeda, Helsinki,
Finland). After connection of the 5F catheter to the
transducer and before thrombin injection, intrasac pres-
sures was recorded in all of the patients, indicating that
blood flow was present inside the sac. Intrasac pressure
was recorded after the performance of each thrombin
injection, usually 3 minutes after the injection (Fig 3).
Both before and after embolization, pressure measure-
ments was recorded in different places, even though the
range of positions for the catheter tip was small. A stable
intrasac pressure in an aneurysm with a previous systolic-
Fig 3. Intrasac pressure monitoring during transcathe
demonstrated inside the sac (122/118 mm Hg). B, A
thrombin, the waveform disappeared, with a stable high
waiting 3 minutes after every single injection before
observed. C, Pressure is about 48 mm Hg after 2 mL thdiastolic waveform pressure or a reduction of at least 50mmHg, or both, were considered as signs of thrombosis
of endoleak, signifying the abolition of arterial blood
flow inside the endoleak itself.
Postoperative surveillance. Immediate imaging
follow-up for all patients undergoing TTE consisted of
an unenhanced CT scan at 24 hours to document the
immediate success of embolization and to identify any
evidence of complications related to the procedure.
Noncontrast CT angiography was performed on a Soma-
tom Plus 4 CT scanner. Acquisition parameters used
were the same in preoperative unenhanced phase spiral
CT scans: 8-mm collimation, 5-mm reconstruction, and
1.5 pitch. The evidence of stable contrast medium inside
the aneurysm sac was defined as an immediate success of
embolization.
After discharge, follow-up for all patients consisted
of clinical examination and CT scans at approximately 1
month, 6 months, and at 1 year. Patients underwent
triphasic CT imaging, with the same standard protocol
followed as for the preoperative imaging. An experienced
radiologist reviewed the images to evaluate maximum
transverse diameter of the aneurysm and identify the
presence and etiology of endoleaks. The clinical success
was identified as the absence of evidence of recurrent
endoleak during follow-up. The maximum aneurysm
diameter was recorded prospectively and compared with
the diameter before TTE in a dedicated workstation
(Leonardo, Siemens, Erlangen, Germany) by comparing
images at the same level using a multitask slice-by-slice
method. Any decrease in diameter of 2 mm was con-
anscaval embolization. A, A systolic/diastolic wave is
approximately 3 minutes from the injection of 1 mL
sure (121 mm Hg). After another 2 mL of thrombin,
suring pressure, a progressive decrease in pressure is
in, and (D) 7 mm Hg after 3 mL thrombin.ter tr
fter
pres
remeasidered significant, as was an initial decrease in diameter.
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Before TTE, four patients had previously undergone
transarterial embolization, but immediate technical success
was achieved in only two patients. In both cases there was a
recurrence of leak on CT scan at 30-days. The transcaval
direct puncture of the aneurysm sac was feasible in 11 of 12
patients (technical success 92%). The transcaval puncture
failed in only one case. In this patient, there was not a tight
adhesion between the caval and aneurysm walls. Thus, the
patient had to undergo direct translumbar embolization of
the aneurysm sac under CT guidance, which was completed
successfully. Before TTE, the mean arterial pressure was
117 mm Hg, and no significant changes were observed
during and after the procedure.
Whenever the puncture of the aneurysm sac was feasi-
ble, intrasac pressures were recorded (Table II). No signif-
icant changes in pressure related to catheter position were
observed before or after embolization. Before treatment,
mean intrasac pressure was 75 31.5mmHg (range, 39 to
125 mm Hg), with evidence of a systolic-diastolic wave in
six of 11 patients. Afferent and efferent branches had been
detected in these patients on preoperative imaging. In the
other 5 patients, stable high pressure was recorded inside
the aneurysm sac, with evidence of blood dripping from the
5F catheter. Three patients had a previous diagnosis of
endotension, whereas in the other two, a type II endoleak
had been demonstrated without any evidence of feeding
collateral vessels.
After TTE, absence of a systolic-diastolic waveform and
a significant reduction in intrasac pressure were observed in
10 of 11 patients, with a mean intrasac pressure of 16.5 
12.2 mm Hg (range, 7 to 40 mm) and a mean pressure
reduction of 58.5 mm Hg. In one patient, the pressure
inside the sac increased throughout the procedure. It was
150 mm Hg after the injection of 5 mL of thrombin, 20
mm Hg more than before starting TTE, therefore, the
procedure was stopped.
We injected between 2 and 5 mL of thrombin to
embolize the endoleak. The mean time to complete TTE
Table II. Intrasac pressure before and after transcatheter
transcaval embolization
Intrasac pressure
Patients Before treatment After treatment
1 140/80 20
2 60 10
3 62 12
4 62 10
5 66 12
6 40/38 36
7 45/40 8
8 130/120 150
9 115/105 40
10 72/60 7
11 90 5was 30 minutes.At unenhanced CT scan 24 hours after treatment,
contrast medium was still seen inside the sac in 10 of 11
patients (Fig 4, A) with an immediate and stable reduction
of intrasac pressure, whereas no stable contrast mediumwas
demonstrated inside the sac in the patient with the increase
in intrasac pressure after TTE.
During the follow-up period at 1 month, we observed
complications in only one (8%) of 12 patients. A thrombo-
phlebitis occurred in the common femoral vein that ex-
tended into the distal tract of the external iliac vein. This
was related to the percutaneous puncture and was success-
fully managed with medical treatment (cefotaxime and
heparin), without any sequelae.
At 1 and 6 months’ follow-up, CT scan highlighted the
recurrence of type II endoleak in only one patient success-
fully treated by TTE. At CT scan 1 year after TTE, no type
II endoleak was found in 10 of 11 patients; furthermore,
the maximum aneurysm diameter was reduced in 10 pa-
tients, with a mean diameter of 68 mm (range, 50 to 88
mm) and a mean reduction of 3 mm (range, 2 to 10 mm;
Fig 4, B). As a result, clinical success of TTE was obtained
in 10 (83%) of 12 patients.
DISCUSSION
The mechanism and behavior of type II endoleak de-
velopment is unknown. Some collateral endoleaks have
been shown to thrombose if left alone, but others will
develop in patients with initially negative CT scans.1,2,7,8
As a result, the management of type II endoleaks is still
controversial. Some authors have suggested repair when
type II endoleaks persist at 12 months after EVAR, despite
a stable aneurysm sac diameter. This is because the collat-
eral vessels transmit arterial pressure to the aneurysm sac,
placing the patient at increased risk for aneurysm rup-
ture.5,9,10
Others believe that treatment should be performed
only when the aneurysm increases in size, even if there is no
evidence of type II endoleak.9,11,12 This condition is de-
fined as endotension.4,7,9,13 It may be due to very slow
retrograde flow inside the sac or to the development of a
hygroma. Because hygromas have become rare after the
placement of the latest generation of stent grafts, we cur-
rently believe that endotension may be due to an unknown
type II endoleak.
It is our view that type II endoleaks should be treated
when their persistence is confirmed after 12months of their
development or when a significant increase in aneurysm sac
diameter is observed after at least 6 months.
Different treatments have been proposed for emboliza-
tion of type II endoleaks.4,6,8,14-17 The more widespread
treatments are transcatheter transarterial and percutaneous
translumbar approaches rather than laparoscopic tying of
collateral branches. The transcatheter transarterial ap-
proach with selective catheterization of the arch of Riolan
and of the IMA permits embolization of the aneurysm sac
and the endovascular exclusion of the origin of the IMA.
This can be achieved by filling the aneurysm sac with
embolization material. Selective embolization with coils
ent
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surgical tying of the IMA, may not be a sufficient treatment
for type II endoleaks because some collateral branches may
lead to reperfusion of the aneurysm.
As reported by Baum et al,8 the embolization of a single
feeding artery is ineffective because additional flow is re-
cruited from nearby vessels, similar to what occurs with
arterial malformations. Therefore, when a type II endoleak
is due to multiple lumbar or hypogastric arteries, or both,
transcatheter selective embolization can be a challenge.18
In such cases, the direct translumbar puncture of the aneu-
rysm sac under fluoroscopic or CT guidance can be at-
tempted as an alternative treatment modality.8,9,14,19 The
placement of the needle/sheath systemwithin the endoleak
cavity can thrombose the endoleak by embolizing the cen-
tral nidus.8
A comparison of transarterial and translumbar tech-
niques demonstrates more recurrences of type II endoleaks
after transcatheter embolization. As a result, direct trans-
lumbar embolization has become the best treatment op-
tion.8 A translumbar transcaval approach with CT guidance
for right-sided aneurysms15 and a transabdominal approach
with ultrasonographic guidance16 have also been reported
as alternatives to translumbar direct puncture of the aneu-
rysm sac.
We proposed TTE for treatment of type II endoleaks.
Compared with transcatheter transarterial embolization, it
is less time consuming and can be performed in patients
with lumbar endoleaks in which no direct lumbar collateral
route exists and in cases of transarterial failure. This point is
highlighted in our series: four patients underwent unsuc-
cessful transarterial procedures before their TTE. TTE also
offers additional advantages over translumbar emboliza-
Fig 4. A computed tomography (CT) scan 24 hours
months. A, Unenhanced CT scan 24-hours after the tre
(arrowhead) inside the aneurysm sac, whose main diamet
through the transcaval puncture and also that there was
an enhanced delayed-phase CT scan demonstrates no rec
aneurysm sac is reduced to 75 mm. TTE clinical success i
hyperdense. This finding may be related to the developmtion. The entire procedure is performed in the angiographysuite in the supine position, under fluoroscopic control; as
a result, patient compliance with the treatment is improved.
The inferior vena cava is only punctured in one site
instead of in two different points, as occurs with the trans-
lumbar transcaval approach.14,15 Therefore, a lower risk of
retroperitoneal hemorrhage is expected. The percutaneous
transfemoral/transjugular access led to a reduction in op-
erator’s radiant dose, and the entire procedure is possible
after transcatheter embolization techniques (Fig 2).
Currently, we prefer transjugular percutaneous access
because it allows a better orientation of the curved needle/
sheath system to the site of puncture. As a result, the
embolization is performed in conditions of safety, under
complete sterility, and enables a choice of materials. In our
opinion, thrombin is an optimal embolizing agent: when
injected in 1-mL boluses, it can spread inside the sac lumen
through the thrombus. Thrombus inside an endoleak sac is
made of a somewhat gelatinous material and in close prox-
imity to the leak it appears to be recently deposited andmay
be subject to ongoing remodeling with repeated cycles of
resorption and deposition. When the endoleak is large or
there is clear evidence of efferent vessels, or both, emboli-
zation should be done by positioning coils inside the aneu-
rysm sac and then injecting thrombin.
The demonstration of stable contrast inside the sac on
unenhanced CT scan at 24 hours is considered as technical
success as well as proof of immediate clinical success. Intra-
procedural evidence of technical success can be obtained by
intrasac pressure monitoring by placing a 5F catheter di-
rectly inside the aneurysm sac. Few reports have been
published about the relationship between intrasac pressure
and endoleak changes.17,20 Intrasac pressure monitoring
transcatheter transcaval embolization (TEE) and at 12
nt highlights stable contrast (asterisks) and gas bubbles
5 mm. That confirms that the aneurysm sac was reached
mediate success of the embolization. B, At 12-months,
ce of endoleaks. Furthermore, the main diameter of the
achieved. Of interest is that the sac walls are thicker and
of a stable thrombus and consequent fibrosis.after
atme
er is 8
an im
urren
s thusshould still be considered as a work in progress.
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Doppler ultrasound waveform analysis of type II endoleaks
has been found and is thought to be predictive of endoleak
behavior.21-26 If flow velocities and resistances are associ-
ated with the dynamics of development and resolution of
type II endoleaks, intrasac pressure changes seem to be an
expression of their evolution. Therefore, the disappearance
of the pressure waveforms and a reduction in intrasac
pressure can be considered as a marker of successful embo-
lization (Fig 3).
Baum et al17 lowered endoleak-induced intra-
aneurysmal sac pressure to 30 mm Hg after successful
embolization of patent arterial branches. We demonstrated
that in patients treated successfully, the disappearance of
systolic-diastolic waveforms or the reduction of intrasac
pressure had been observed during TTE. If these promising
results are confirmed in a larger number of patients, intrasac
pressure measurement might become an effective method
to monitor the natural history of type II endoleaks.
Nevertheless, we have to keep in mind that measure-
ment may be compromised by several pitfalls. The disap-
pearance of the pressure waveform can be mainly due to the
exclusion of the endoleak by blood flow but also by contact
of the catheter tip with the aneurysmal wall, even in in-
stances where there is persistent blood flow or the presence
of thrombin inside the catheter. To reduce the impact of
these two pitfalls on the reliability of the procedure, we
rotated the catheter tip to record the presence of residual
blood flow and we washed the catheter with saline after
every thrombin injection.
The TTE is viable in almost all patients. As for trans-
lumbar embolization of the aneurysm sac, direct puncture
is quite difficult when the aneurysm sac diameter is small
and is associated with an increased risk of stent graft punc-
ture. Furthermore, the transcatheter transcaval approach
should be carefully evaluated when the aneurysm sac is
completely left-sided to demonstrate a tight adhesion be-
tween the caval and aneurysmal wall. In fact, the asymmet-
rical increase of the aneurysm sac might be associated with
a decrease of adhesion between the aneurysm and caval
walls, so that TTE technical success might be compro-
mised. In our experience, the puncture failed in only one
patient because of the incomplete adhesion between the
caval vein and the aneurysm sac. A careful re-evaluation of
CT images highlighted that the aneurysm sac was almost
completely left-sided and that there was a minimum dis-
tance of 3 mm between the caval vein and aneurysm sac
walls. As a consequence, we think that in such cases direct
translumbar puncture of the aneurysm sac should be con-
sidered as the first approach proposed for embolization of
type II endoleaks.
The only complication we reported in our series was
thrombophlebitis at the site of femoral percutaneous ve-
nous access. Other possible complications related to TTE
are retroperitoneal hemorrhage and caval-aortic fistulas. If
there is a tight adhesion between the caval walls and the
aneurysm sac, the development of a retroperitoneal hem-
orrhage should rarely occur. It is also worth noticing thatTTE requires a thin needle cannula and a 5F catheter,
which are quite small in caliber and cause only small holes in
the caval walls. Even though diameters of these devices are
a little larger than the 18G to 20G needles used for direct
translumbar puncture, the caval hole is expected to close
immediately after the removal of the 5F catheter. Like
Stavropoulos et al,15 we did not report any caval-aortic
fistulas in our study.
A cavography at the end of the procedure, as well as CT
scan at 24 hours after treatment can check for both of these
complications and treatment can be undertaken by place-
ment of coils or a device like those to close inter-atrial
cardiac shunts. According to our experience, TTE appears
quite safe and less invasive than the translumbar transcaval
approach;15; nevertheless, further studies are needed to
confirm the small rate of clinical complications.
The current study has certain limitations. We have
already mentioned some bias related to our technique of
measuring intrasac pressure. The small number of patients
treated cannot support a certain conclusion of success or
complication rates. Nonetheless, our study population is
comparable with other study groups reported in the litera-
ture of patients with persistent type II endoleak who re-
quired treatment.8,9,14,15,18,27-29
We did not prospectively analyze different approaches
for embolization of a type II endoleak: we just enrolled all
consecutive patients with a persistent endoleak who re-
quired treatment according to the criteria adopted at our
center. We then compared technical and clinical success
with the results reported both for transarterial transcatheter
embolization and translumbar direct puncture of the aneu-
rysm sac (Table III). Our aim was to consider if the TTE
was at least as feasible and successful as other approaches in
common clinical practice.
CONCLUSION
Currently, no treatment is considered the gold stan-
dard for type II endoleak management; as a result, a tai-
lored treatment should be preferred. Different approaches
have been proposed for embolization of type II en-
doleaks.4,6,8,14-17 We evaluated TTE and it appears to be a
promising and feasible technique for thrombosis of type II
endoleaks, especially if a transjugular percutaneous access is
used. According to the results of our study, TTE technical
and clinical success rates are comparable with other treat-
ment strategies (Table III), and it can be proposed as the
first-line therapy in most patients or at least as an alternative
to translumbar direct puncture of the aneurysm sac.
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